...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Haematology >Anticoagulation for prevention and treatment of cancer-related venous thromboembolism
【24h】

Anticoagulation for prevention and treatment of cancer-related venous thromboembolism

机译：抗凝剂预防和治疗癌症相关的静脉血栓栓塞

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The close relationship between malignancy and venous thromboembolism (VTE) is well established, with malignancy increasing VTE risk and accounting for a substantial proportion of presentations with VTE. Moreover, VTE impacts significantly on morbidity and mortality in cancer patients. Anticoagulation for prevention and treatment of VTE requires a patient-centred approach due to the heterogeneous patient population and inherent increased thrombotic and bleeding risks. In recent years, low molecular weight heparin (LMWH) injections have come to be the mainstay for treatment and prevention of cancer-related VTE. For treatment, this is usually administered for at least 6 months and continued in patients with active cancer or those receiving treatment for cancer. The use of LMWH for thromboprophylaxis in hospitalised cancer patients is also well accepted, but out-of-hospital prophylaxis remains contentious. The development of risk assessment models may help identify the patients at highest risk. The role of the new oral factor Xa and thrombin inhibitors in this setting remains to be determined.
机译：恶性肿瘤与静脉血栓栓塞症（VTE）之间的密切关系已得到很好的确立，恶性肿瘤增加了VTE风险，并占了VTE表现的很大一部分。此外，VTE显着影响癌症患者的发病率和死亡率。预防和治疗VTE的抗凝治疗需要以患者为中心的方法，因为患者人群异质且固有的血栓形成和出血风险增加。近年来，低分子量肝素（LMWH）注射已成为治疗和预防癌症相关VTE的主要手段。为了治疗，通常将其给药至少6个月，并在患有活动性癌症或接受癌症治疗的患者中继续治疗。在住院的癌症患者中使用LMWH进行血栓预防也广为接受，但院外预防仍存在争议。风险评估模型的开发可能有助于识别风险最高的患者。在这种情况下，新型口服因子Xa和凝血酶抑制剂的作用尚待确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号